Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

The major development of the past decade in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) was the introduction of cetuximab in combination with platinum plus 5-fluorouracil chemotherapy (CT), followed by maintenance cetuximab (the “E...

Full description

Bibliographic Details
Main Authors: Athanassios Argiris, Kevin J. Harrington, Makoto Tahara, Jeltje Schulten, Pauline Chomette, Ana Ferreira Castro, Lisa Licitra
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-05-01
Series:Frontiers in Oncology
Subjects:
cetuximab
squamous cell carcinoma of the head and neck
immune checkpoint inhibitor
EXTREME
platinum-refractory
recurrent and/or metastatic
Online Access:http://journal.frontiersin.org/article/10.3389/fonc.2017.00072/full

Internet

http://journal.frontiersin.org/article/10.3389/fonc.2017.00072/full

Similar Items